Hybio Pharmaceutical Co.. Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Net Sales

133.68

239.47

308.33

214.97

119.50

102.37

148.81

Other Operating Income

0.00

Total Operating income

133.68

239.47

308.33

214.97

119.50

102.37

148.81

Raw Material Cost

68.06

98.61

148.54

119.93

68.04

60.43

77.17

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

22.57

25.27

25.25

27.07

26.28

26.98

26.16

Selling and Distribution Expenses

68.62

26.71

45.36

70.53

37.14

45.01

34.91

Other Expenses

0.47

-0.73

-1.07

-0.17

-1.12

-0.85

-1.05

Total Expenditure (Excl Depreciation)

163.97

143.31

208.47

215.81

120.26

123.98

127.70

Operating Profit (PBDIT) excl Other Income

-30.299999999999997

96.19999999999999

99.9

-0.8

-21.6

21.099999999999998

Other Income

-11.25

16.19

4.54

7.89

6.68

49.57

-4.61

Operating Profit (PBDIT)

-51.51

142.65

135.14

-70.21

42.03

65.69

49.31

Interest

22.57

25.27

25.25

27.07

26.28

26.98

26.16

Exceptional Items

-0.06

0.22

-0.00

0.00

Gross Profit (PBDT)

65.62

140.87

159.79

95.05

51.47

41.94

71.64

Depreciation

0.00

33.13

39.18

32.74

Profit Before Tax

-74.13

84.48

76.76

-136.47

-23.43

5.96

-9.60

Tax

2.41

8.53

6.91

9.44

1.08

2.40

4.75

Provisions and contingencies

0.00

Profit After Tax

-74.12

75.60

69.87

-138.85

-24.45

3.74

-14.10

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-74.12

75.60

69.87

-138.85

-24.45

3.74

-14.10

Share in Profit of Associates

0.00

Minority Interest

-0.64

-0.52

-0.43

-5.41

-0.41

-0.36

-0.25

Other related items

0.00

Consolidated Net Profit

-74.76

75.08

69.44

-144.26

-24.86

3.38

-14.35

Equity Capital

0.00

Face Value

1.0

Reserves

649.15

723.77

648.40

578.63

706.93

754.04

747.95

Earnings per share (EPS)

-0.08

0.09

0.08

-0.16

-0.03

0.0

-0.02

Diluted Earnings per share

-0.08

0.09

0.08

-0.16

-0.03

0.0

-0.02

Operating Profit Margin (Excl OI)

-30.11%

38.98%

31.61%

-54.56%

-3.21%

-16.24%

14.23%

Gross Profit Margin

-55.46%

49.11%

35.64%

-45.25%

13.18%

37.81%

15.55%

PAT Margin

-55.44%

31.57%

22.66%

-64.59%

-20.46%

3.66%

-9.48%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Sep 2025 is -44.18% vs -22.32% in Jun 2025

Consolidate Net Profit

QoQ Growth in quarter ended Sep 2025 is -199.60% vs 8.21% in Jun 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is -131.86% vs -3.14% in Jun 2025

Interest

QoQ Growth in quarter ended Sep 2025 is -10.67% vs 0.40% in Jun 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

Compare Quarterly Results Of Hybio Pharmaceutical Co.. Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

133.68

Other Operating Income

0.00

Total Operating income

133.68

Raw Material Cost

68.06

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

22.57

Selling and Distribution Expenses

68.62

Other Expenses

0.47

0.00

0.47

Total Expenditure (Excl Depreciation)

163.97

Operating Profit (PBDIT) excl Other Income

-30.29

0.00

-30.29

Other Income

-11.25

Operating Profit (PBDIT)

-51.51

Interest

22.57

Exceptional Items

-0.06

Gross Profit (PBDT)

65.62

Depreciation

0.00

Profit Before Tax

-74.13

Tax

2.41

Provisions and contingencies

0.00

Profit After Tax

-74.12

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-74.12

Share in Profit of Associates

0.00

Minority Interest

-0.64

Other related items

0.00

Consolidated Net Profit

-74.76

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

649.15

Earnings per share (EPS)

-0.08

Diluted Earnings per share

-0.08

Operating Profit Margin (Excl OI)

-30.11%

0.00

-30.11%

Gross Profit Margin

-55.46%

0.00

-55.46%

PAT Margin

-55.44%

0.00

-55.44%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 13.37 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -44.18% vs -22.32% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 11.88% vs 56.62% in Sep 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit -7.48 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -199.60% vs 8.21% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -200.40% vs 83.04% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) -4.03 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -131.86% vs -3.14% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -214.16% vs 164.89% in Sep 2024

Quarterly - Interest

Interest 2.26 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -10.67% vs 0.40% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -14.07% vs -18.32% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) -30.11%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

YoY Growth in quarter ended Sep 2025 has fallen from Sep 2024